Video

CAR T-Cell Data in Multiple Myeloma
Leslie Lauersdorf discusses key considerations for nurses and navigators surrounding the use of CAR T-cell therapy in multiple myeloma. Read More ›

Latest Developments in Multiple Myeloma
Leslie Lauersdorf provides an overview of some of the most exciting clinical developments in multiple myeloma based on data presented at ASH 2019. Read More ›

Working Together to Find the New Standard of Care
Dr Andrey Antov values the benefits of working within an interdisciplinary team to advance cancer care and help patients. Read More ›

Opportunities Are Abundant for Navigators in the Field of Genetics and Genomics
Dr Andrey Antov sees much potential for navigators when it comes to applying genetic and genomic testing to cancer care. Read More ›

Healthcare Team's Relationship to the Patient
Dr Andrey Antov expands on how the healthcare team can work together to provide the best possible care for their patient. Read More ›

The Navigator's Role in Genetic Testing
Dr Andrey Antov recognizes how important the role of the navigator is in dealing with genetic and genomic testing, as the navigator often needs to help the patient gain access to the appropriate therapy, work with different stakeholders, monitor data, and more. Read More ›

Why Are Clinical Trials Important?
Dr Andrey Antov believes it's important for patients to participate in clinical trials for a multitude of reasons, as clinical trials can benefit both the patient and the healthcare system as a whole. Read More ›

Educating Oncology Professionals on Genetic and Genomic Testing
Dr Andrey Antov provides an overview of the role of Jackson Laboratory in the field of cancer genetic testing and in the education of nurses and navigators who co-manage patients at high risk or with a diagnosis of cancer. Read More ›

Who Should Consider Genetic Testing?
Dr Andrey Antov identifies situations in which people may want to consider genetic testing. Read More ›

What the Next Generation of Cancer Biomarkers May Involve
Dr Sanjiv Agarwala predicts that the cancer biomarkers of the future may be “mobile biomarkers,” meaning measures of the tumor microenvironment or immune response that change with therapy and may be able to determine treatment efficacy. Read More ›

Page 3 of 10


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: